Table 2

Virological response in patients with genotype 2 (GT2) infection who completed therapy with sofosbuvir (SOF) and ribavirin (RBV)

Treatment durationSOF plus RBV for 12 weeks (N=283) SOF plus RBV for 16 weeks (N=38) Total population (N=321)
Overall SVR12 rate (EP)*250/283 (88.3%)33/38 (86.8%)283/321 (88.2%)
Overall SVR12 rate (PP)†250/271 (92.3%)33/36 (91.7%)283/307 (92.2%)
Non-cirrhoticCirrhoticNon-cirrhoticCirrhotic
SVR12 rate by cirrhosis status (EP)91.0% (201/221)79.0% (49/62)92.9% (13/14)83.3% (20/24)
SVR12 rate by cirrhosis status (PP)93.9% (201/214)86.0% (49/57)100% (13/13)87.0% (20/23)
Treatment naïveTreatment exp.Treatment naïveTreatment exp.Treatment naïveTreatment exp.Treatment naïveTreatment exp.
SVR12 rate by cirrhosis status and prior treatment experience (EP)*91.9% (159/173)87.5% (42/48)71.9% (23/32)86.7% (26/30)90.9% (10/11)100% (3/3)100% (7/7)76.5% (13/17)
SVR12 rate (PP) by cirrhosis status and prior treatment experience†95.8% (159/166)87.5% (42/48)76.7% (23/30)96.3% (26/27)100% (10/10) 100% (3/3)100% (7/7)81.3% (13/16)92.2% (283/307)
Virological failure
 Breakthrough112
 Relapse756321
 Non-response11
Non-virological failure‡7231114
  • *Evaluable population (EP): patients who completed treatment excluding those lost to on-treatment follow-up or who withdrew consent and have virological outcome or are confirmed by site to be lost to post-treatment follow-up (counted as non-virological treatment failures).

  • Per protocol (PP) population patients who completed treatment early due to virological failure or completed treatment and have virological outcome.

  • ‡Lost to post-treatment follow-up (n=14).

  • SVR12, sustained virological response 12 weeks after therapy.